200698-35-7

Upstream product

• 200698-34-6 2,4-di(benzyloxycarbonyl)butylphosphinic acid 
• 100-51-6 benzyl alcohol 
• 173039-05-9 dibenzyl 2-methylenepentanedioate 

Downstream Products

• 1001850-66-3 2-(benzyloxy-hydroxy-phosphorylmethyl)-pentanedioic acid dibenzyl ester 
• 229472-51-9 4,4'-phosphinicobis(butane-1,3-dicarboxylic acid) 
• 200698-36-8 2,4-di(benzyloxycarbonyl)butyl[hydroxy(phenyl)methyl]benzylphosphinic acid 
• 263393-92-6 5-[Benzyloxy-(2,4-bis-benzyloxycarbonyl-butyl)-phosphinoyl]-4-benzyloxycarbonyl-pentanoic acid benzyl ester 

Relevant academic research and scientific papers

BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES

GCPII inhibitors comprising 2-(phosphonomethyl) pentanedioic acid (2-PMPA) conjugated to a bile acid and their use for treating a disease or condition associated with elevated levels of GCPII, including inflammatory bowel disease.

DENDRIMER BASED COMPOSITIONS AND METHODS OF USING THE SAME

The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and monitoring the response to therapy of a cell or tissue (e.g., a tumor).

DENDRIMER BASED COMPOSITIONS AND METHODS OF USING THE SAME

The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The c

Design and pharmacological activity of phosphinic acid based NAALADase inhibitors

A novel series of phosphinic acid based inhibitors of the neuropeptidase NAALADase are described in this work. This series of compounds is the most potent series of inhibitors of the enzyme described to date. In addition, we have shown that these compounds are protective in animal models of neurodegeneration. Compound 34 significantly prevented neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In addition, in the chronic constrictive model of neuropathic pain, compound 34 significantly attenuated the hypersensitivity observed with saline-treated animals. These data suggest that NAALADase inhibition may provide a new approach for the treatment of both neurodegenerative disorders and peripheral neuropathies.